Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

967 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extracellular Vesicle Capture by AnTibody of CHoice and Enzymatic Release (EV-CATCHER): A customizable purification assay designed for small-RNA biomarker identification and evaluation of circulating small-EVs.
Mitchell MI, Ben-Dov IZ, Liu C, Ye K, Chow K, Kramer Y, Gangadharan A, Park S, Fitzgerald S, Ramnauth A, Perlin DS, Donato M, Bhoy E, Manouchehri Doulabi E, Poulos M, Kamali-Moghaddam M, Loudig O. Mitchell MI, et al. Among authors: donato m. J Extracell Vesicles. 2021 Jun;10(8):e12110. doi: 10.1002/jev2.12110. Epub 2021 Jun 3. J Extracell Vesicles. 2021. PMID: 34122779 Free PMC article.
Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Fanning SL, Korngold R, Yang Z, Goldgirsh K, Park S, Zenreich J, Baker M, McKiernan P, Tan M, Zhang B, Donato ML, Perlin DS. Fanning SL, et al. Among authors: donato ml. PLoS Pathog. 2021 Oct 29;17(10):e1010025. doi: 10.1371/journal.ppat.1010025. eCollection 2021 Oct. PLoS Pathog. 2021. PMID: 34714894 Free PMC article.
Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Donato ML, Park S, Baker M, Korngold R, Morawski A, Geng X, Tan M, Ip A, Goldberg S, Rowley S, Chow K, Brown E, Zenreich J, McKiernan P, Buttner K, Ullrich A, Long L, Feinman R, Ricourt A, Kemp M, Vendivil M, Suh H, Balani B, Cicogna C, Sebti R, Al-Khan A, Sperber S, Desai S, Fanning S, Arad D, Go R, Tam E, Rose K, Sadikot S, Siegel D, Gutierrez M, Feldman T, Goy A, Pecora A, Biran N, Leslie L, Gillio A, Timmapuri S, Boonstra M, Singer S, Kaur S, Richards E, Perlin DS. Donato ML, et al. JCI Insight. 2021 Mar 22;6(6):e143196. doi: 10.1172/jci.insight.143196. JCI Insight. 2021. PMID: 33571168 Free PMC article. Clinical Trial.
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KM, Bhattacharyya P, Yang X, Donato ML, Rowley SD, Carini C, Valentinetti M, Smith J, Gadaleta G, Bejot C, Stives S, Timberg M, Kdiry S, Pecora AL, Beaven AW, Goy A. Feldman T, et al. Among authors: donato ml. Br J Haematol. 2014 Jul;166(1):77-83. doi: 10.1111/bjh.12846. Epub 2014 Mar 25. Br J Haematol. 2014. PMID: 24661044 Free PMC article. Clinical Trial.
A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Richter J, Skarbnik AP, Pecora A, Siegel DS. Biran N, et al. Biol Blood Marrow Transplant. 2016 Dec;22(12):2165-2171. doi: 10.1016/j.bbmt.2016.08.017. Epub 2016 Aug 31. Biol Blood Marrow Transplant. 2016. PMID: 27590107 Free article. Clinical Trial.
A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma.
Biran N, Rowley SD, Vesole DH, Zhang S, Donato ML, Skarbnik AP, Richter J, Pecora A, Siegel DS. Biran N, et al. Bone Marrow Transplant. 2019 Nov;54(11):1881-1891. doi: 10.1038/s41409-019-0534-0. Epub 2019 May 17. Bone Marrow Transplant. 2019. PMID: 31101891 Clinical Trial.
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
Biran N, Gourna Paleoudis E, Feinman R, Vesole DH, Zenreich J, Wang S, Ahn J, Bansal M, Rowley S, Donato M, Pecora AL, Richter J, Anand P, McBride L, Ivanovski K, Korngold R, Siegel DS. Biran N, et al. Among authors: donato m. Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17. Am J Hematol. 2021. PMID: 34435374 Free article. Clinical Trial. No abstract available.
The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
Donato ML, Siegel DS, Vesole DH, McKiernan P, Nyirenda T, Pecora AL, Baker M, Goldberg SL, Mato A, Goy A, Rowley SD. Donato ML, et al. Biol Blood Marrow Transplant. 2014 Aug;20(8):1211-6. doi: 10.1016/j.bbmt.2014.04.027. Epub 2014 May 2. Biol Blood Marrow Transplant. 2014. PMID: 24792872 Free article.
967 results